Previous PostNovember 29, 2022: MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
Next PostPooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program
